Natus Medical Competitors

CONMED (NYSE:CNMD) and Natus Medical (NASDAQ:NTUS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.

Volatility & Risk

CONMED has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500. Comparatively, Natus Medical has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500.

Insider & Institutional Ownership

89.7% of Natus Medical shares are owned by institutional investors. 5.4% of CONMED shares are owned by insiders. Comparatively, 1.5% of Natus Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares CONMED and Natus Medical's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings and target prices for CONMED and Natus Medical, as reported by MarketBeat.

CONMED currently has a consensus target price of $103.25, suggesting a potential downside of 18.70%. Given CONMED's stronger consensus rating and higher probable upside, equities analysts clearly believe CONMED is more favorable than Natus Medical.

Valuation & Earnings

This table compares CONMED and Natus Medical's gross revenue, earnings per share and valuation.

CONMED has higher revenue and earnings than Natus Medical. Natus Medical is trading at a lower price-to-earnings ratio than CONMED, indicating that it is currently the more affordable of the two stocks.

Summary

CONMED beats Natus Medical on 12 of the 14 factors compared between the two stocks.

Natus Medical (NASDAQ:NTUS) and InMode (NASDAQ:INMD) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.

Earnings and Valuation

This table compares Natus Medical and InMode's top-line revenue, earnings per share and valuation.

InMode has lower revenue, but higher earnings than Natus Medical. Natus Medical is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Natus Medical and InMode, as provided by MarketBeat.com.

InMode has a consensus target price of $71.50, indicating a potential downside of 13.96%. Given InMode's stronger consensus rating and higher possible upside, analysts plainly believe InMode is more favorable than Natus Medical.

Insider and Institutional Ownership

89.7% of Natus Medical shares are owned by institutional investors. Comparatively, 35.7% of InMode shares are owned by institutional investors. 1.5% of Natus Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Natus Medical has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, InMode has a beta of 1.95, suggesting that its share price is 95% more volatile than the S&P 500.

Profitability

This table compares Natus Medical and InMode's net margins, return on equity and return on assets.

Summary

InMode beats Natus Medical on 11 of the 14 factors compared between the two stocks.

Natus Medical (NASDAQ:NTUS) and Outset Medical (NASDAQ:OM) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

Analyst Recommendations

This is a breakdown of current recommendations for Natus Medical and Outset Medical, as reported by MarketBeat.

Outset Medical has a consensus price target of $57.80, suggesting a potential upside of 7.70%. Given Outset Medical's stronger consensus rating and higher probable upside, analysts plainly believe Outset Medical is more favorable than Natus Medical.

Insider and Institutional Ownership

89.7% of Natus Medical shares are owned by institutional investors. Comparatively, 84.6% of Outset Medical shares are owned by institutional investors. 1.5% of Natus Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Natus Medical and Outset Medical's revenue, earnings per share (EPS) and valuation.

Outset Medical has lower revenue, but higher earnings than Natus Medical.

Profitability

This table compares Natus Medical and Outset Medical's net margins, return on equity and return on assets.

Summary

Natus Medical beats Outset Medical on 5 of the 9 factors compared between the two stocks.

BioLife Solutions (NASDAQ:BLFS) and Natus Medical (NASDAQ:NTUS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Profitability

This table compares BioLife Solutions and Natus Medical's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings and recommmendations for BioLife Solutions and Natus Medical, as reported by MarketBeat.

BioLife Solutions presently has a consensus price target of $46.6667, indicating a potential upside of 49.05%. Given BioLife Solutions' stronger consensus rating and higher possible upside, analysts clearly believe BioLife Solutions is more favorable than Natus Medical.

Earnings and Valuation

This table compares BioLife Solutions and Natus Medical's gross revenue, earnings per share and valuation.

BioLife Solutions has higher earnings, but lower revenue than Natus Medical. Natus Medical is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

67.7% of BioLife Solutions shares are held by institutional investors. Comparatively, 89.7% of Natus Medical shares are held by institutional investors. 22.3% of BioLife Solutions shares are held by insiders. Comparatively, 1.5% of Natus Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility and Risk

BioLife Solutions has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, Natus Medical has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.

Summary

BioLife Solutions beats Natus Medical on 9 of the 14 factors compared between the two stocks.

AxoGen (NASDAQ:AXGN) and Natus Medical (NASDAQ:NTUS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings.

Analyst Ratings

This is a summary of recent ratings and price targets for AxoGen and Natus Medical, as provided by MarketBeat.

AxoGen presently has a consensus target price of $23.75, suggesting a potential upside of 33.88%. Given AxoGen's stronger consensus rating and higher possible upside, equities analysts clearly believe AxoGen is more favorable than Natus Medical.

Profitability

This table compares AxoGen and Natus Medical's net margins, return on equity and return on assets.

Risk & Volatility

AxoGen has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, Natus Medical has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500.

Earnings & Valuation

This table compares AxoGen and Natus Medical's gross revenue, earnings per share (EPS) and valuation.

Natus Medical has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Natus Medical, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

78.4% of AxoGen shares are owned by institutional investors. Comparatively, 89.7% of Natus Medical shares are owned by institutional investors. 6.9% of AxoGen shares are owned by insiders. Comparatively, 1.5% of Natus Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Natus Medical beats AxoGen on 8 of the 14 factors compared between the two stocks.

TransMedics Group (NASDAQ:TMDX) and Natus Medical (NASDAQ:NTUS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, analyst recommendations, risk, institutional ownership, profitability and earnings.

Insider and Institutional Ownership

76.7% of TransMedics Group shares are held by institutional investors. Comparatively, 89.7% of Natus Medical shares are held by institutional investors. 13.1% of TransMedics Group shares are held by company insiders. Comparatively, 1.5% of Natus Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares TransMedics Group and Natus Medical's gross revenue, earnings per share (EPS) and valuation.

Natus Medical has higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than Natus Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares TransMedics Group and Natus Medical's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings for TransMedics Group and Natus Medical, as provided by MarketBeat.com.

TransMedics Group currently has a consensus target price of $44.20, indicating a potential upside of 79.82%. Given TransMedics Group's stronger consensus rating and higher possible upside, equities research analysts clearly believe TransMedics Group is more favorable than Natus Medical.

Volatility & Risk

TransMedics Group has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. Comparatively, Natus Medical has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.